Skip to main content

Clinical pharmacist interventions in managing drug-related problems in hospitalized patients with neurological diseases.

Research Abstract
Abstract Background Drug-related problems (DRPs) are common in hospitalized patients with neurological diseases. Clinical pharmacy services could minimize drug-related harm and improve patient care. Objective To identify common DRPs in neurology and document clinical pharmacists' medication-related interventions. Setting The wards and intensive care unit of the Department of Neurology at Assiut University Hospital. Method Prospective study of clinical pharmacists' interventions during the routine care work of reviewing patients medical charts over a period of 6 months from January to June 2017. Main outcome measure The frequency and severity of DRPs and clinical pharmacists' recommendations. Results Out of 1421 reviewed medications charts, a total of 414 DRPs were detected for 285 admitted patients. The most common DRPs were drug selection problems (36.7%) and dosing errors (27.5%). The majority of DRPs (71.7%) were categorized as causing no patient harm. Clinical pharmacists provided recommendations for the detected problems that ranged from drug monitoring to stop and starting new medicines. About 90% of pharmacists' interventions were accepted by physicians. Poisson regression of factors that may influence the frequency of DRPs revealed significant associations of patient age (p = 0.03) and the number of comorbid diseases (p = 0.01). Conclusions Prescribing errors in neurology inpatient are likely to occur. Clinical pharmacists' interventions assisted in early detection of drug problems and prevention of the consequent patient harms.
Research Authors
Ali MAS1, Khedr EMH2, Ahmed FAH2, Mohamed NNE2.
Research Journal
Int J Clin Pharm. 2018 Oct;40(5):1257-1264. doi: 10.1007/s11096-018-0658-0. Epub 2018 Jun 19.
Research Member
Research Pages
2018 Oct;40(5):1257-1264.
Research Publisher
Springerlink
Research Rank
1
Research Vol
2018 Oct;40(5):1257-1264.
Research Website
pubmed central
Research Year
2018

Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.

Research Abstract
Abstract Tardive syndromes (TDS) typically manifest 3 months or later after exposure to antipsychotic drugs, and unfortunately have no satisfactory medical treatment. We explored the possibility of using therapeutic repetitive transcranial magnetic stimulation (rTMS). Twenty-six patients were allocated to receive real or sham rTMS over the hand/arm area of motor cortex (M1). Each received a daily total of 2000 rTMS pulses (20 Hz at 100% rMT: 1000 stimuli per hemisphere) for 10 consecutive days. Outcome was assessed using the Abnormal Involuntary Movement Scale (AIMS) and TMS measures of M1 excitability. Three patients in the sham group failed to complete the study. At baseline, there was no significant difference between the groups in age, sex distribution, duration of illness, AIMS score and drug treatment. rTMS improved symptoms in both groups. However, there was a greater reduction in the AIMS score of the real rTMS group compared with the sham group (real, 8.3 ± 1.7 points; sham 1.2 ± 3.3; repeated measure analysis ANOVA Time X Group interaction P = 0.001). The same trends were observed in the clinical subscales. Following treatment, MEP amplitudes at higher intensities (140, and 150%) increased more in the real treatment group than in the sham group. This is the first clinical trial study of bilateral hemispheric rTMS in patients with TDS and suggests that 20 Hz rTMS might be a feasible treatment option in patients unresponsive to "first-line" treatment.Clinical trial registration ClinicalTrials.gov Identifier: NCT03145311.
Research Authors

Khedr EM1,2, Al Fawal B3, Abdelwarith A3, Saber M3, Rothwell JC4.
Research Journal
J Neural Transm (Vienna). 2019 Feb;126(2):183-191. doi: 10.1007/s00702-018-1941-x. Epub 2018 Oct 13.
Research Pages
2019 Feb;126(2):183-191.
Research Publisher
Elsevier
Research Rank
1
Research Vol
2019 Feb;126(2):183-191.
Research Website
pubmed central
Research Year
2019

Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.

Research Abstract
Abstract Tardive syndromes (TDS) typically manifest 3 months or later after exposure to antipsychotic drugs, and unfortunately have no satisfactory medical treatment. We explored the possibility of using therapeutic repetitive transcranial magnetic stimulation (rTMS). Twenty-six patients were allocated to receive real or sham rTMS over the hand/arm area of motor cortex (M1). Each received a daily total of 2000 rTMS pulses (20 Hz at 100% rMT: 1000 stimuli per hemisphere) for 10 consecutive days. Outcome was assessed using the Abnormal Involuntary Movement Scale (AIMS) and TMS measures of M1 excitability. Three patients in the sham group failed to complete the study. At baseline, there was no significant difference between the groups in age, sex distribution, duration of illness, AIMS score and drug treatment. rTMS improved symptoms in both groups. However, there was a greater reduction in the AIMS score of the real rTMS group compared with the sham group (real, 8.3 ± 1.7 points; sham 1.2 ± 3.3; repeated measure analysis ANOVA Time X Group interaction P = 0.001). The same trends were observed in the clinical subscales. Following treatment, MEP amplitudes at higher intensities (140, and 150%) increased more in the real treatment group than in the sham group. This is the first clinical trial study of bilateral hemispheric rTMS in patients with TDS and suggests that 20 Hz rTMS might be a feasible treatment option in patients unresponsive to "first-line" treatment.Clinical trial registration ClinicalTrials.gov Identifier: NCT03145311.
Research Authors

Khedr EM1,2, Al Fawal B3, Abdelwarith A3, Saber M3, Rothwell JC4.
Research Journal
J Neural Transm (Vienna). 2019 Feb;126(2):183-191. doi: 10.1007/s00702-018-1941-x. Epub 2018 Oct 13.
Research Member
Research Pages
2019 Feb;126(2):183-191.
Research Publisher
Elsevier
Research Rank
1
Research Vol
2019 Feb;126(2):183-191.
Research Website
pubmed central
Research Year
2019

Fatigue in Rheumatoid Arthritis Patients: Association With Sleep Quality, Mood Status, and Disease Activity.
[Article in English, Spanish]

Research Abstract
Abstract OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by polyarthritis and systemic manifestations. RA-fatigue is a significant problem and adds on disease burden. Sleep disturbance, depression, and disease activity are suggested contributing factors to RA-fatigue; however, their combined role did not examine before among Egyptian RA patients. The objective of the study was to investigate the presence of fatigue, sleep and mood disturbances in RA patients. Also, to evaluate the possible association of poor sleep, depression, and disease activity with RA-fatigue. METHODS: This cross-sectional study included 115 RA patients diagnosed according to the 2010 ACR-EULAR criteria and 46 age and sex matched controls. Fatigue using the Multidimensional Assessment of Fatigue-Global Fatigue Index, sleep using the Pittsburgh Sleep Quality Index and mood status using Beck Depression Inventory were assessed for all participants. RA disease activity was evaluated using disease activity score-28 joints. RESULTS: RA patients had higher mean fatigue, sleep disturbance, and depression scores (27.2±8.9, 6.4±3.6, and 12.8±7.3; respectively) than controls (22.7±7, 4.8±3, 7.8±5.9; respectively) (P.05). Poor sleep, depression and higher disease activity were significantly correlated with fatigue (r=0.4, r=0.65, r=0.55; respectively) (P.001). The three variables may explain up to 49.1% of the variation in fatigue on multiple regression analysis. CONCLUSION: Fatigue, poor sleep, and depression are more common in Egyptian patients with RA. A remarkably higher fatigue was associated with poor sleep, depression, and high disease activity, thus monitoring these silent comorbidities in clinical practice is required.
Research Authors
Hammam N1, Gamal RM2, Rashed AM2, Elfetoh NA3, Mosad E4, Khedr EM3.
Research Journal
Reumatol Clin. 2018 Aug 20. pii: S1699-258X(18)30169-4.
Research Pages
NULL
Research Publisher
Elsevier
Research Rank
1
Research Vol
2018 Aug 20.
Research Website
pubmed central
Research Year
2018

Changes in recruitment of motor cortex excitation and inhibition in patients with drug-induced tardive syndromes.

Research Abstract
Abstract OBJECTIVES: It has recently been suggested that drug-induced tardive syndromes (TS) might be due to maladaptive plasticity, which increases motor excitability in cerebral cortex and basal ganglia. In order to test this hypothesis, we performed the first measurements of cortical excitability in TS. METHODS: Motor cortex excitability was examined using transcranial magnetic stimulation (TMS) in 22 TS patients and compared with that in 20 age and sex-matched healthy individuals. Resting and active motor threshold (RMT, AMT) and input-output curves (I/O curves) assessed corticospinal excitability. The duration of the contralateral silent period (cSP) at a range of stimulation intensities and ipsilateral silent period (iSP) were used as measures of inhibition. RESULTS: There were no significant differences in RMT and AMT between patients and controls, although the input-output curves were significantly steeper in patients. The cSP (at different stimulus intensities) and iSP were both longer in the patients compared to the control group. However, most of this difference could be accounted for by increased recruitment of motor evoked potentials (MEPs) in patients. CONCLUSION: TS is characterized by hyperexcitability of corticospinal output that might contribute to the lack of selectivity in muscle recruitment and contribute to excess involuntary movement. The findings are opposite to those in naturally-occurring hyperkinesia such as Sydenham's and Huntington's chorea, suggesting a fundamental difference in the pathophysiology.
Research Authors
Khedr EM1, Al Fawal B2, Abdelwarith AM2, Saber M2, Tony AAH2, El-Bassiony A3, Rothwell JC4.
Research Journal
Neurophysiol Clin. doi: 10.1016/j.neucli.2018.10.001. Epub 2018 Oct 23.
Research Member
Research Pages
2019 Feb;49(1):33-40.
Research Publisher
Elsevier
Research Rank
1
Research Vol
2019 Feb;49(1):33-40.
Research Website
pubmed central
Research Year
2019

Sci Rep. 2018 Nov 8;8(1):16525. doi: 10.1038/s41598-018-35003-4.
K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt.
Rösler TW1,2, Salama M3,4, Shalash AS5, Khedr EM6, El-Tantawy

Research Abstract
Abstract Pesticide exposure is associated with increased risk of Parkinson's disease (PD). We investigated in Egypt whether common variants in genes involved in pesticide detoxification or transport might modify the risk of PD evoked by pesticide exposure. We recruited 416 PD patients and 445 controls. Information on environmental factors was collected by questionnaire-based structured interviews. Candidate single-nucleotide polymorphisms (SNPs) in 15 pesticide-related genes were genotyped. We analyzed the influence of environmental factors and SNPs as well as the interaction of pesticide exposure and SNPs on the risk of PD. The risk of PD was reduced by coffee consumption [OR = 0.63, 95% CI: 0.43-0.90, P = 0.013] and increased by pesticide exposure [OR = 7.09, 95% CI: 1.12-44.01, P = 0.036]. The SNP rs1126680 in the butyrylcholinesterase gene BCHE reduced the risk of PD irrespective of pesticide exposure [OR = 0.38, 95% CI: 0.20-0.70, P = 0.002]. The SNP rs1803274, defining K-variant BCHE, interacted significantly with pesticide exposure (P = 0.007) and increased the risk of PD only in pesticide-exposed individuals [OR = 2.49, 95% CI: 1.50-4.19, P = 0.0005]. The K-variant BCHE reduces serum activity of butyrylcholinesterase, a known bioscavenger for pesticides. Individuals with K-variant BCHE appear to have an increased risk for PD when exposed to pesticides.
Research Authors
Rösler TW1,2, Salama M3,4, Shalash AS5, Khedr EM6, El-Tantawy A7, Fawi G8, El-Motayam A9, El-Seidy E10, El-Sherif M7, El-Gamal M4, Moharram M4, El-Kattan M4, Abdel-Naby M4, Ashour S5, Müller U11, Dempfle A12, Kuhlenbäumer G13, Höglinger GU14,15,16.
Research Journal
Sci Rep.
Research Member
Research Pages
16525
Research Publisher
Nature publishing group
Research Rank
1
Research Vol
2018 Nov 8;8(1):16525.
Research Website
pubmed central
Research Year
2018

Dynamic Communications Between GABAA Switch, Local Connectivity, and Synapses During Cortical Development: A Computational Study.

Research Abstract
Abstract Several factors regulate cortical development, such as changes in local connectivity and the influences of dynamical synapses. In this study, we simulated various factors affecting the regulation of neural network activity during cortical development. Previous studies have shown that during early cortical development, the reversal potential of GABAA shifts from depolarizing to hyperpolarizing. Here we provide the first integrative computational model to simulate the combined effects of these factors in a unified framework (building on our prior work: Khalil et al., 2017a,b). In the current study, we extend our model to monitor firing activity in response to the excitatory action of GABAA. Precisely, we created a Spiking Neural Network model that included certain biophysical parameters for lateral connectivity (distance between adjacent neurons) and nearby local connectivity (complex connections involving those between neuronal groups). We simulated different network scenarios (for immature and mature conditions) based on these biophysical parameters. Then, we implemented two forms of Short-term synaptic plasticity (depression and facilitation). Each form has two distinct kinds according to its synaptic time constant value. Finally, in both sets of networks, we compared firing rate activity responses before and after simulating dynamical synapses. Based on simulation results, we found that the modulation effect of dynamical synapses for evaluating and shaping the firing activity of the neural network is strongly dependent on the physiological state of GABAA. Moreover, the STP mechanism acts differently in every network scenario, mirroring the crucial modulating roles of these critical parameters during cortical development. Clinical implications for pathological alterations of GABAergic signaling in neurological and psychiatric disorders are discussed.
Research Authors
Khalil R1, Karim AA1,2, Khedr E3, Moftah M4, Moustafa AA5,6.
Research Journal
Front Cell Neurosci. 2018
Research Member
Research Pages
468
Research Publisher
Frontiers open acess Free PMC Article Similar articles Icon for Frontiers
Research Rank
1
Research Vol
Dec 17;12:468
Research Website
pubmed central
Research Year
2018


The Effect of 20 Hz versus 1 Hz Repetitive Transcranial Magnetic Stimulation on Motor Dysfunction in Parkinson's Disease: Which Is More Beneficial?

Research Abstract
Abstract BACKGROUND: There is evidence that both high and low frequency rTMS may have therapeutic effects on motor performance of Parkinson's disease. OBJECTIVE: The aim of the study was to conduct the first direct comparison of the two approaches. METHODS: 52 PD patients were randomly classified into two groups. The first group received 20 Hz and the 2nd group received 1 Hz rTMS with a total of 2000 pulses over M1of each hemisphere for ten days. Effects were assessed with the Unified Parkinson's Disease Rating Scale part III (UPDRS), Instrumental Activity of Daily Living (IADL), and a self-assessment score (SA) before, after the last session, and one month later. Cortical excitability was measured before and after the end of sessions. RESULTS: There was a significant improvement on all rating scales after either 1 Hz or 20 Hz rTMS, but the effect persisted for longer after 20 Hz (treatment X time interaction for UPDRS and IADL (P = 0.075 and 0.04, respectively). Neither treatment affected motor thresholds, but 20 Hz rTMS increased MEP amplitude and the duration of transcallosal inhibition. In an exploratory analysis, each group was subdivided into akinetic-rigid and tremor dominant subgroups and the effects of 1 Hz and 20 Hz treatment recalculated. There was weak evidence that patients with an akinetic-rigid presentation may respond better than those with predominant tremor. CONCLUSION: Both 20 Hz and 1 Hz rTMS improve motor function in PD, but 20 Hz rTMS is more effective.
Research Authors
Khedr EM1,2, Al-Fawal B2, Abdel Wraith A2, Saber M2, Hasan AM1, Bassiony A3, Nasr Eldein A1, Rothwell JC4.
Research Journal
J Parkinsons Dis. 2019;9(2):379-387. doi: 10.3233/JPD-181540.
Research Member
Research Pages
379-387.
Research Publisher
IOS
Research Rank
1
Research Vol
2019;9(2):379-387.
Research Website
pubmed
Research Year
2019

Therapeutic Role of Transcranial Direct Current Stimulation in Alzheimer Disease Patients: Double-Blind, Placebo-Controlled Clinical Trial.

Research Abstract
Abstract OBJECTIVE: To explore the neuropsychological effects and levels of tau protein (TAU), amyloid β 1-42 (Aβ 1-42), and lipid peroxidase after 10 sessions of anodal transcranial direct current stimulation (tDCS) in patients with mild to moderate Alzheimer disease (AD). PATIENTS AND METHODS: A total of 46 consecutive patients with probable AD participated in this study. They were classified randomly into 2 equal groups: active versus sham. Each patient received 10 sessions of anodal tDCS over the left and right temporoparietal region for 20 minutes for each side with the cathode on the left arm. Patients were assessed using the Modified Mini Mental State Examination (MMMSE), clock drawing test, Montreal Cognitive Scale (MoCA), and the Cornell Scale for depression. Serum TAU, Aβ 1-42, and lipid peroxidase were measured before and after the 10th session. RESULTS: There was a significant improvement in the total score of each cognitive rating scale (MMMSE, clock drawing test, and MoCA) in the real group, whereas no such change was observed in the sham group. The Cornell depression score improved significantly in both groups. There was a significant increase in serum Aβ 1-42 ( P = .02) in the real but not in the sham group, with a significant Treatment condition × Time interaction ( P = .009). There was no significant effect on tau or lipid peroxidase in either group but a significant positive correlation between changes of Aβ1-42 and MMMSE ( P = .005) and MoCA ( P = .02). CONCLUSION: The observed cognitive improvements were complemented by parallel changes in serum levels of Aβ 1-42. TRIAL REGISTRATION: ClinicalTrials.gov NCT03313518.
Research Authors
Khedr EM1, Salama RH2, Abdel Hameed M1, Abo Elfetoh N1, Seif P1.
Research Journal
Neurorehabil Neural Repair. 2019 May;33(5):384-394.
Research Pages
384-394.
Research Publisher
Sage Journal
Research Rank
1
Research Vol
2019 May;33(5):
Research Website
pubmed
Research Year
2019

Therapeutic Role of Transcranial Direct Current Stimulation in Alzheimer Disease Patients: Double-Blind, Placebo-Controlled Clinical Trial.

Research Abstract
Abstract OBJECTIVE: To explore the neuropsychological effects and levels of tau protein (TAU), amyloid β 1-42 (Aβ 1-42), and lipid peroxidase after 10 sessions of anodal transcranial direct current stimulation (tDCS) in patients with mild to moderate Alzheimer disease (AD). PATIENTS AND METHODS: A total of 46 consecutive patients with probable AD participated in this study. They were classified randomly into 2 equal groups: active versus sham. Each patient received 10 sessions of anodal tDCS over the left and right temporoparietal region for 20 minutes for each side with the cathode on the left arm. Patients were assessed using the Modified Mini Mental State Examination (MMMSE), clock drawing test, Montreal Cognitive Scale (MoCA), and the Cornell Scale for depression. Serum TAU, Aβ 1-42, and lipid peroxidase were measured before and after the 10th session. RESULTS: There was a significant improvement in the total score of each cognitive rating scale (MMMSE, clock drawing test, and MoCA) in the real group, whereas no such change was observed in the sham group. The Cornell depression score improved significantly in both groups. There was a significant increase in serum Aβ 1-42 ( P = .02) in the real but not in the sham group, with a significant Treatment condition × Time interaction ( P = .009). There was no significant effect on tau or lipid peroxidase in either group but a significant positive correlation between changes of Aβ1-42 and MMMSE ( P = .005) and MoCA ( P = .02). CONCLUSION: The observed cognitive improvements were complemented by parallel changes in serum levels of Aβ 1-42. TRIAL REGISTRATION: ClinicalTrials.gov NCT03313518.
Research Authors
Khedr EM1, Salama RH2, Abdel Hameed M1, Abo Elfetoh N1, Seif P1.
Research Journal
Neurorehabil Neural Repair. 2019 May;33(5):384-394.
Research Pages
384-394.
Research Publisher
Sage Journal
Research Rank
1
Research Vol
2019 May;33(5):
Research Website
pubmed
Research Year
2019
Subscribe to